Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Feb;61(2):155-7.
doi: 10.1136/thx.2005.043372. Epub 2005 Dec 29.

Improving rate of decline of FEV1 in young adults with cystic fibrosis

C Que  1 , P Cullinan, D Geddes
Affiliations

Improving rate of decline of FEV1 in young adults with cystic fibrosis

C Que et al. Thorax. 2006 Feb.

Abstract

Background: CF is characterised by a progressive decline in lung function; reductions in this decline are often used as a measure of success in clinical trials. With improvements in treatment it may be that there has been a temporal shift in the pattern of the disease.

Methods: 318 patients born in five successive cohorts and attending a specialist clinic with at least two routine measurements of lung function made between the ages of 18 and 22 were included. The declines in their lung function were estimated and compared.

Results: The mean (SE) slopes for percentage predicted forced expiratory volume in 1 second (FEV(1)) and forced vital capacity (FVC) were -1.53 (0.36)% and -1.27 (0.34)%, respectively (NS). The annual deterioration in FEV(1) was -2.49%, -1.99% -2.20%, -1.65%, and -0.65% from the earliest to the most recent birth cohort; a similar pattern was observed for changes in FVC. There were no differences between male and female patients. Patients infected with Pseudomonas had a greater average decline in FEV(1) (-1.6% v -1.1%).

Conclusions: The rates of decline in lung function in young adults with CF have diminished with successive birth cohorts. This has important implications for the design of clinical studies in this disease.

PubMed Disclaimer

Conflict of interest statement

Competing interests: none

References

    1. Milla C E, Warwick W J. Risk of death in cystic fibrosis patients with severely compromised lung function. Chest 19981131230–1234. - PubMed
    1. Rosenbluth D B, Wilson K, Ferkol T.et al Lung function decline in cystic fibrosis patients and timing for lung transplantation referral. Chest 2004126412–419. - PubMed
    1. Augarten A, Akons H, Aviram M.et al Prediction of mortality and timing of referral for lung transplantation in cystic fibrosis patients. Pediatr Transplant 20015339–342. - PubMed
    1. Davis P B, Byard P J, Konstan M W. Identifying treatments that halt progression of pulmonary disease in cystic fibrosis. Pediatr Res 199741161–165. - PubMed
    1. Konstan M W, Byard P J, Hoppel C L.et al Effect of high‐dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995332848–854. - PubMed